Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. — CFSMEATLAS
Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome.
Demitrack, M A, Crofford, L J · Annals of the New York Academy of Sciences · 1998 · DOI
Quick Summary
This study found that people with ME/CFS have reduced activity in their stress-response system—a network in the brain called the HPA axis that normally helps the body cope with physical and emotional challenges. The researchers discovered that this underactive response pattern is different from what happens in depression, and it may explain why stress and exertion worsen ME/CFS symptoms. The findings suggest that problems with specific brain chemicals involved in stress regulation may contribute to the condition.
Why It Matters
Understanding HPA axis dysfunction in ME/CFS is crucial because it provides a biological mechanism explaining why patients experience symptom exacerbation with stress and physical activity. This mechanistic insight could guide development of targeted treatments aimed at restoring normal stress-response function, moving beyond symptomatic management to address underlying pathophysiology.
Observed Findings
Patients with ME/CFS demonstrate reduced HPA axis activity compared to controls
HPA axis dysregulation in ME/CFS differs from the pattern seen in melancholic depression
HPA dysfunction shares features with fibromyalgia
Evidence suggests impaired central nervous system drive contributes to the HPA dysfunction
Disturbances in serotonergic neurotransmission and AVP signaling may underlie the HPA axis dysregulation
Inferred Conclusions
HPA axis dysregulation is an essential neuroendocrine feature of ME/CFS pathophysiology
The HPA dysfunction is characterized by reduced central nervous system drive rather than global endocrine failure
Alterations in monoaminergic and neuropeptide systems contribute to HPA dysregulation in ME/CFS
Targeting HPA axis dysfunction may lead to more effective treatments for the condition
Remaining Questions
What initiates HPA axis dysregulation in ME/CFS, and why do some individuals develop the condition while others do not?
How do serotonergic and AVP system disturbances mechanistically lead to reduced HPA output?
What This Study Does Not Prove
This study does not prove that HPA dysregulation is the sole cause of ME/CFS or explain how this dysfunction initially develops. It does not establish whether observed HPA changes are primary drivers of illness or secondary consequences, nor does it directly test whether correcting HPA function would improve symptoms.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →